Julia Murphy
Medical · Newport Beach, CANPI 1619566726
Payments from drug & device makers
Across 369 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$2K
- Medtronic$2K
- Novo Nordisk$1K
- Lilly USA, LLC$842
- Corcept Therapeutics$829
- Mannkind Corporation$815
- plus $3K from 34 others
What the payments were for
- Travel & lodging$2,61625%
- Food & beverage$7,63674%
- Education$350%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$2,027
- MINIMED 780G$718
- Korlym$500
- Ozempic$249
- FREESTYLE LIBRE 3$152
- RECORLEV$125
- DEXCOM G7 GSS (161)$124
- Wegovy$111
How this compares
$10,346 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 367 | $490,170 |
| MounjaroTirzepatide | 321 | $427,746 |
| JardianceEmpagliflozin | 155 | $185,069 |
| FarxigaDapagliflozin Propanediol | 81 | $86,515 |
| RybelsusSemaglutide | 38 | $73,735 |
| TrulicityDulaglutide | 56 | $73,511 |
| AfrezzaInsulin Regular, Human | 36 | $58,173 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $50,413 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $40,831 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $40,827 |
| JanuviaSitagliptin Phosphate | 31 | $35,831 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $34,638 |
| WegovySemaglutide | 26 | $32,801 |
| Gvoke Hypopen 2-PackGlucagon | 41 | $25,839 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $19,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,060 | $596,707431 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $842 | $530,402434 claims |
| Boehringer IngelheimJardiance, Tradjenta | $45 | $198,247166 claims |
| AstraZenecaFarxiga | $117 | $86,51581 claims |
| Mannkind CorporationAfrezza | $815 | $58,17336 claims |
| AbbVieSynthroid | $41 | $3,78959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.
Other medical in Newport Beach
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.